The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients
Neoangiogenesis is a crucial therapeutic target for metastatic colorectal cancer as demonstrated by the effectiveness of biologic drugs with exclusive or partial antiangiogenic activity such as bevacizumab, aflibercept, and regorafenib. Metronomic chemotherapy may be an alternative strategy for targeting tumor angiogenesis and several clinical studies suggested its promising activity and its extremely favorable toxicity profile in the treatment of metastatic colorectal cancer patients.
KeywordsmCRC Patient Oral Cyclophosphamide Favorable Toxicity Profile Metronomic Chemotherapy Metastatic Colorectal Cancer Patient
- 5.Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506PubMedCrossRefGoogle Scholar
- 17.Marmorino F, Cremolini C, Loupakis F, Salvatore L (2013) Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): results of a phase II trial. J Clin Oncol 31(Suppl): abstr e14577. ASCO 2013 2013Google Scholar
- 20.Falcone A, Cremolini C, Gianluca M (2013) FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the phase III TRIBE trial by GONO group. J Clin Oncol 31(Suppl): abstr 3505. ASCO 2013 2013Google Scholar
- 21.Koopman M, Simkens LHJ, Ten Tije AJ (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31(Suppl); abstr 3502. ASCO 2013 2013Google Scholar